Quotient adds drug substance to integrated development platform

21-Feb-2022

The platform was developed in consultation with the MHRA & FDA and employs a rapid “make-test” cycle

Quotient adds drug substance to integrated development platform

Quotient Sciences, a global drug development and manufacturing organisation, has integrated drug substance into its Translational Pharmaceutics platform. The integrated service now combines drug substance, drug product and clinical testing activities within a unified organisation under a single project manager.

The service integration follows a year after the company’s acquisition of its Alnwick, UK site and provides a more streamlined approach from candidate selection through to commercialisation.

“Our Translational Pharmaceutics platform is now in its 15th year and has accelerated development timelines for more than 500 drug programmes. We remain the only outsourcing partner able to offer innovators the ability to manufacture, release, and dose under one organisation. This approach is proven to shave 12-months of timelines and, by adding drug substance synthesis, the timeline from candidate selection to clinic can be a further accelerated by 2-4 months,” commented Mark Egerton, CEO of Quotient Sciences.

The platform was developed in consultation with the MHRA & FDA and employs a rapid “make-test” cycle, where drug products are manufactured, released, and dosed in a clinical study in days rather than months. This means biotechs and pharma companies can fast track molecules from First in Human (FIH) through Proof of Concept (POC).

“By fully integrating drug substance with drug product and clinical testing activities, Quotient Sciences can closely align manufacturing and dosing workflows, greatly improving R&D efficiencies, and increasing the potential for clinical and commercial success,” said Peter Scholes, CSO of Quotient Sciences. “In fact, an independent study by the Tufts Center of the Study of Drug Development (CSDD) showed Translational Pharmaceutics delivered $200m in drug development cost saving per approved drug.”

Sign up for your free email newsletter

“Our purpose has always been to bring new medicines to patients faster, and our new capabilities in drug substance continue to break down traditional industry silos. As we look to the future, Quotient will continue to bring on new services that further integrate drug development and streamline the outsourcing needs of our customers,” added Egerton.

Featured Companies